PMID- 35278648
OWN - NLM
STAT- MEDLINE
DCOM- 20220524
LR  - 20220603
IS  - 1878-5492 (Electronic)
IS  - 0966-3274 (Linking)
VI  - 72
DP  - 2022 Jun
TI  - De novo human leukocyte antigen allosensitization patterns in patients bridged to 
      heart transplantation using left ventricular assist devices.
PG  - 101567
LID - S0966-3274(22)00041-7 [pii]
LID - 10.1016/j.trim.2022.101567 [doi]
AB  - INTRODUCTION: We examined the impact and time course of de novo human leukocyte 
      antigen (HLA) allosensitization following left ventricular assist device (LVAD) 
      implantation. METHODS AND RESULTS: Forty patients had a calculated panel reactive 
      antibody (cPRA) prior to LVAD surgery between January 2014 and December 2018. Of 
      these patients, we retrospectively studied 33 patients who had pre-LVAD cPRA 
      <10%. De novo allosensitization was defined as cPRA >/=10% within 3 months 
      following LVAD surgery, and "persistent allosensitization" was defined as cPRA 
      >/=10% at time of heart transplant or death. One-third (11/33) of our cohort 
      developed de novo allosensitization within 3-months post-LVAD. Median duration of 
      follow-up during LVAD support was 588 days (IQR 337-1071 days), or approximately 
      19 months. In an adjusted, multivariable analysis, female sex remained associated 
      with de novo allosensitization (adjusted odds ratio [95%CI]: 11 (1.4-85), 
      P = 0.026). De novo allosensitization was subsequently associated with persistent 
      allosensitization (P = 0.024). Both axial-flow and centrifugal-flow LVADs had 
      similar rates of allosensitization. Compared to those with no allosensitization, 
      patients with de novo allosensitization did not appear to have inferior 
      post-transplant outcomes of death or treated rejection. CONCLUSION: In our 
      single-center experience, one-third of patients developed de novo 
      allosensitization which did not appear to associate with inferior post-transplant 
      outcomes. Female sex was associated with de novo allosensitization.
CI  - Copyright (c) 2022 Elsevier B.V. All rights reserved.
FAU - Chau, Vinh Q
AU  - Chau VQ
AD  - Advocate Heart Institute, Advocate Christ Medical Center, Oak Lawn, IL, United 
      States of America.
FAU - Feinman, Jason
AU  - Feinman J
AD  - Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at 
      Mount Sinai, New York, NY, United States of America.
FAU - Fullin, Kerianne
AU  - Fullin K
AD  - Division of Cardiology, Department of Medicine, University of Pittsburgh Medical 
      Center, Pittsburgh, PA, United States of America.
FAU - Mahmood, Kiran
AU  - Mahmood K
AD  - Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at 
      Mount Sinai, New York, NY, United States of America.
FAU - Oliveros, Estefania
AU  - Oliveros E
AD  - Heart and Vascular Institute, Section of Cardiology, Lewis Katz School of 
      Medicine, Philadelphia, PA, United States of America.
FAU - Mitter, Sumeet S
AU  - Mitter SS
AD  - Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at 
      Mount Sinai, New York, NY, United States of America.
FAU - Pinney, Sean P
AU  - Pinney SP
AD  - Division of Cardiology, Department of Medicine, University of Chicago Medical 
      Center, Chicago, IL, United States of America.
FAU - Mancini, Donna M
AU  - Mancini DM
AD  - Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at 
      Mount Sinai, New York, NY, United States of America; Department of Population 
      Health Science, Icahn School of Medicine at Mount Sinai, New York, NY, United 
      States of America.
FAU - Lala, Anuradha
AU  - Lala A
AD  - Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at 
      Mount Sinai, New York, NY, United States of America; Department of Population 
      Health Science, Icahn School of Medicine at Mount Sinai, New York, NY, United 
      States of America.
FAU - Moss, Noah
AU  - Moss N
AD  - Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at 
      Mount Sinai, New York, NY, United States of America. Electronic address: 
      noah.moss@mountsinai.org.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220309
PL  - Netherlands
TA  - Transpl Immunol
JT  - Transplant immunology
JID - 9309923
RN  - 0 (Antibodies)
RN  - 0 (HLA Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Histocompatibility Antigens Class II)
SB  - IM
MH  - Antibodies
MH  - Female
MH  - HLA Antigens
MH  - *Heart Transplantation
MH  - *Heart-Assist Devices
MH  - Histocompatibility Antigens Class I
MH  - Histocompatibility Antigens Class II
MH  - Humans
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Antibody
OT  - Heart failure
OT  - Heart transplantation
OT  - Left ventricular assist device
OT  - Sensitization
EDAT- 2022/03/13 06:00
MHDA- 2022/05/25 06:00
CRDT- 2022/03/12 20:10
PHST- 2021/10/26 00:00 [received]
PHST- 2022/02/24 00:00 [revised]
PHST- 2022/02/28 00:00 [accepted]
PHST- 2022/03/13 06:00 [pubmed]
PHST- 2022/05/25 06:00 [medline]
PHST- 2022/03/12 20:10 [entrez]
AID - S0966-3274(22)00041-7 [pii]
AID - 10.1016/j.trim.2022.101567 [doi]
PST - ppublish
SO  - Transpl Immunol. 2022 Jun;72:101567. doi: 10.1016/j.trim.2022.101567. Epub 2022 
      Mar 9.